MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Mass spectrometry-based screening for α-synuclein bioactive marine natural products

    F. Ferretti, M. Xu, D. Prebble, G. Mellick, A. Carroll (Gold Coast, Australia)

    Objective: This study identifies marine-derived natural products with binding affinity and aggregation-inhibition activity against α-synuclein (α-syn) using a mass spectrometry (MS)-based screening approach. The objective…
  • 2025 International Congress

    TMS-EEG Provides Objective Neurophysiological Measures of Motor Fluctuations in Parkinson’s Disease

    M. Roitman, S. Anis, A. Suminski, N. Zifman, H. Fogel, T. Fay-Karmon, S. Hassin-Baer (Ramat Gan, Israel)

    Objective: To assess the correlates TMS evoked potentials (TEPs) measurements changes representing interhemispheric transmission to the change in motor symptoms in 'off' versus 'on' states.…
  • 2025 International Congress

    Comparison of Microglial PET Imaging in Parkinson’s Disease, RBD, and Controls with a CSF1R and TSPO Ligand.

    K. Mills, I. Cheong, Y. Du, J. Coughlin, A. Horti, C. Motley, R. Dannals, W. Lesniak, T. Dawson, M. Pomper (Baltimore, USA)

    Objective: To compare regional binding patterns of microglial PET radioligands: [11C]DPA-713, a TSPO ligand, and [11C]CPPC1, a CSF1R ligand  in people with Parkinson’s disease (PD).…
  • 2025 International Congress

    Clinical Profile and 18F -Fluorodopa Positron Emission Tomography (18F -DOPA PET) Findings in a Movement Disorder Clinic Patient Cohort

    S. Yellaturi, M. Prabhu, A. Behera, S. Pandey (Faridabad, India)

    Objective: This study aimed to evaluate the utility of 18F -DOPA PET in patients with diagnostic uncertainty at our movement disorder clinic in India. Background:…
  • 2025 International Congress

    Impact of Aquaporin-4 polymorphisms on Glymphatic Function and Motor Symptoms in Parkinson’s Disease

    J. Qin, M. Zhang (Hangzhou, China)

    Objective: This study aims to investigate whether single-nucleotide polymorphisms (SNPs) of the Aquaporin-4(AQP4) gene were related to abnormal protein accumulation (α-synuclein), glymphatic dysfunction (DTI-ALPS), and…
  • 2025 International Congress

    Mining Metabolomics GWAS for Key Parkinson’s Disease Variants: A Bioinformatics Approach to Genetic-Metabolic Associations

    S. Rodríguez-Quiroga, T. Ascencio, J. Largo Gonzalez, S. Peña Martinez, L. Hernandez Delgado, A. Noyce, M. Tan (Buenos Aires, Argentina)

    Objective: To propose a novel approach to explore genetic-metabolic interactions in Parkinson’s disease (PD) by integrating the largest genome-wide association studies (GWASs) for PD and…
  • 2025 International Congress

    Hispanic Recruitment to PD GENEration at Columbia University

    A. Arroyo, H. Lee, M. Dini, L. Caboy, K. Ghosh Galvelis, R. de Leon, J. Agin-Liebes (New York, USA)

    Objective: To evaluate the effect of having a Hispanic, Spanish-speaking research coordinator on recruitment of Hispanic and Latinx people with Parkinson's disease to the PD…
  • 2025 International Congress

    Longitudinal Analysis of Disease Progression in GBA-Associated Early-Onset Parkinson’s Disease

    YM. Sun, PH. Li, ZY. Qi, FT. Liu, JJ. Wu, J. Wang (Shanghai, China)

    Objective: This study aims to investigate the longitudinal disease progression of early-onset Parkinson’s disease (EOPD) in carriers of GBA mutations compared to genetically undefined EOPD…
  • 2025 International Congress

    VPS13C: a Modifier Gene causing Suboptimal Response to Levodopa in Early-Onset Parkinson’s Disease

    L. Malfer, C. Piat, O. Ross, Z. Niu, E. Benarroch, R. Savica (Jacksonville, USA)

    Objective: To describe a retrospective clinical study of four cases carrying heterozygous pathogenic variants in the VPS13C gene with a clinical diagnosis of Early-Onset Parkinson’s…
  • 2025 International Congress

    The Global Parkinson’s Genetics Program: Expanding the Diversity of Neurological Disorder Data: 2025 Update

    GP2. Parkinson'S_genetics_program (Chevy Chase, USA)

    Objective: To broaden the available data for Parkinson's Disease (PD) and related disorders by integrating genetic data from more than 115,000 participants worldwide through genotyping…
  • « Previous Page
  • 1
  • …
  • 132
  • 133
  • 134
  • 135
  • 136
  • …
  • 181
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley